Corient Private Wealth
IMRX icon

Corient Private Wealth’s Immuneering IMRX Stock Holding History

Corient Private Wealth’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,870
Closed -$236K – 2935
2025
Q4 		$236K Sell
35,870
-220
-0.6% -$1.41K ﹤0.01% 2561
2025
Q3 		$253K Sell
36,090
-27,650
-43% -$143K ﹤0.01% 2222
2025
Q2 		$215K Buy
+63,740
New +$109K ﹤0.01% 2198
2025
Q1 		– Sell
-63,740
Closed -$140 – 2359
2024
Q4 		$140 Hold
63,740
– – ﹤0.01% 2351
2024
Q3 		$159K Buy
63,740
+20,370
+47% +$29.6K ﹤0.01% 2261
2024
Q2 		$55.5K Hold
43,370
– – ﹤0.01% 2252
2024
Q1 		$125K Buy
43,370
+14,000
+48% +$78.4K ﹤0.01% 2161
2023
Q4 		$216K Sell
29,370
-15,284
-34% -$102K ﹤0.01% 2036
2023
Q3 		$343K Hold
44,654
– – ﹤0.01% 1689
2023
Q2 		$453K Sell
44,654
-2,000
-4% -$19.2K ﹤0.01% 1498
2023
Q1 		$453K Sell
46,654
-765
-2% -$4.34K ﹤0.01% 1425
2022
Q4 		$230K Buy
+47,419
New +$420K ﹤0.01% 1441

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Corient Private Wealth's IMRX Position: Q1 2026 in Review

Corient Private Wealth sold out of Immuneering (IMRX) in Q1 2026, closing a stake of 35,870 shares — an estimated $236K sold.

Corient Private Wealth first reported a position in IMRX in Q4 2022 and held it in 12 quarters. The position peaked at $453K in Q1 2023. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Corient Private Wealth reported no remaining Immuneering position as of Q1 2026 after selling out during the quarter.
  • Corient Private Wealth sold 35,870 Immuneering shares in Q1 2026, an estimated $236K.
  • Corient Private Wealth first reported a position in Immuneering in Q4 2022 and held it in 12 quarters.
  • Corient Private Wealth's Immuneering position peaked at $453K in Q1 2023.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.